What Has Been Insulin Drugs Market in Recent Years?
The insulin drugs market has seen considerable growth due to a variety of factors.
• The market size of insulin drugs has experienced substantial growth lately. The market value is anticipated to increase from $35 billion in 2024 to $37.29 billion in 2025, with a compound annual growth rate (CAGR) of 6.6%.
The growth during the historic period was due to factors such as the increasing prevalence of diabetes, expansion of emerging markets, growing elderly population, and the surge in the development of insulin analogues.
What Is the Forecasted Market Size and Growth Rate for The Insulin Drugs Market?
The insulin drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for insulin drugs is projected to experience significant growth in the upcoming years, anticipating to reach $46.47 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 5.7%.
The expected growth during this projected period can be ascribed to factors such as the rising disease burden, initiatives by the government, and escalation in research & development and partnerships. Prominent trends for this forecasted duration involve introducing new products to widen their scope of offerings, expanding the product range and business through mergers and takeovers, utilizing strategic alliances to boost product offerings, injecting more resources into research and development to innovate new methods of insulin delivery, funding in advanced solutions to minimize research & development expenses, and speeding up the development process.
What Factors Are Driving Growth In The Insulin Drugs Market?
Altered lifestyle trends are leading to a rise in the incidence of diabetes, thus likely to fuel the need for diabetes medication in the forthcoming years. Excessive work hours, inadequate physical exercise, and unhealthy dietary and beverage habits primarily trigger diabetes. A particular study highlighted a significant occurrence of diabetes among people living a sedentary lifestyle. Furthermore, individuals who are obese have a heightened risk, up to 80 times, of contracting type 2 diabetes. World Health Organization (WHO) report suggests that in the UK, by 2030, it is predicted that 74% of men and 64% of women will be overweight, which is a major contributing factor to diabetes. These elements are projected to expand the number of diabetes patients, consequently stimulating the diabetes treatments market in the forecast period.
What Are The Main Segments Of The Global Insulin Drugs Market?
The insulin drugs market covered in this report is segmented –
1) By Product Type: Basal Or Long-Acting Insulins, Bolus Or Fast-Acting Insulins, Pre-Mixed, And Intermediate And Short Acting Insulins
2) By Source Type: Insulin Analogs, And Human Insulin
4) By Drug Classification: Branded Drugs, And Generic Drugs
3) By Application: Type 2 Diabetes, Type 1 Diabetes, And Gestational Diabetes
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, And Online
Subsegments:
1) By Basal Or Long-Acting Insulins: Insulin Glargine, Insulin Detemir, Insulin Degludec
2) By Bolus Or Fast-Acting Insulins: Insulin Aspart, Insulin Lispro, Insulin Glulisine
3) By Pre-Mixed: Biphasic Insulin Formulations, Pre-Mixed Combinations Of Long-Acting And Fast-Acting Insulins
4) By Intermediate And Short-Acting Insulins: Insulin NPH (Neutral Protamine Hagedorn), Regular Insulin (Short-Acting)
Pre-Book The Insulin Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Insulin Drugs Market?
The Insulin market is witnessing a rising trend in mergers and acquisitions involving new formula developments. Businesses are pouring resources into innovations in the insulin medication industry. An illustration of this is the research conducted at Lund University Diabetes Centre in Sweden, where they used CRISPR, a genome modification tool. This intervention managed to disable a key gene that causes diabetes, effectively reducing beta cell mortality and enhancing insulin production in the pancreas. Novo Nordisk, an insulin manufacturing company, has created a diabetes tablet, set to be introduced in India by February 2022. This tablet falls under the category of blockbuster drugs, glucagon-like peptide-1 (GLP-1s), known for triggering insulin production. The newly created drug is predicted to generate approximately $5 billion in yearly sales.
Who Are the Key Players in the Insulin Drugs Market?
Major companies operating in the insulin drugs market include:
• Novo Nordisk
• Sanofi S.A.
• Eli Lilly And Company
• Biocon Ltd
• and Gan & Lee Pharmaceuticals
• Bioton
• Wockhardt Ltd
• Julphar
• Tonghua Dongbao Pharmaceutical
• AstraZeneca
• NIPRO
• Olympus Medical Systems
• Hitachi Medico
• Nihon Kohden
• Fukuda Denshi
• Emperra GmbH E-Health Technologies
• DIABNEXT™
• Berlin-Chemie AG
• Ypsomed Holding AG
• Patients Pending Ltd
• Dexcom
• Johnson and Johnson
• Medtronic
• Abbott Laboratories
• Acon Laboratories
• Tandem Diabetes Care. Inc.
• Becton
• Dickinson
• Insulet Corporation
• AJA Pharma
• SEDICO Pharmaceutical Company
• Pfizer
What Is The Most Dominant Region In The Insulin Drugs Market?
North America was the largest region in the insulin drugs market in 2024. Middle East is expected to be the largest growing region in the global insulin drugs market share during the forecast period. The regions covered in the insulin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
